Bloomberg zojuist:
Genfit Gains as Takeover Talk of French Biotech Company Persists
2017-03-13 13:47:06.488 GMT
By Johannes Koch
(Bloomberg) -- French biotechnology stock climbs as much as
9.5% in Paris, may be gaining as rumors about potential takeover
interest persist, Arsene Guekam, analyst at Kepler Cheuvreux
says by phone.
* Interest in developmental drug Elafibranor is high as co. is
targeting non-alcoholic fatty liver disease, set to become
one of the most important treatment areas in coming years,
Guekam says
* Says no near-term catalysts of note that may be impacting
shares
* Shares in co. rise as much as 9.5% to as much as EU32, the
biggest intraday gain since March 2, when shares soared 33%
on takeover rumors
* Shares are up 49% YTD, up 47% MTD
* Genfit did not immediately respond to a call or email for
comment
* NOTE: Genfit M&A may be costly NOTE: Novartis, Shire, Sanofi
may interested in Genfit